- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01611467
A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects (AME/FE)
Study Overview
Status
Intervention / Treatment
Detailed Description
This will be a single-center, 2-part, open-label, randomized (Part 1 only), 2-treatment study in healthy adult males (n = 18). Within no more than 28 days (Day -28) prior to the start of Part 1 or Part 2, subjects will undergo routine screening procedures including physical examination, 12-lead electrocardiograms (ECGs), vital signs, clinical laboratory safety tests (serum chemistry, hematology, and urinalysis), serology screen, fasting glucose levels (including HbA1C) and drug and alcohol screen.
In Part 1, subjects (n = 6) will receive Treatment A (Cohort 1) under fasted conditions. Treatment A: A single 20-mg oral dose of CC-223 capsule containing a microtracer of [14C]- CC-223 solution. For Part 1, subjects will be domiciled at the study center from Day -1 until the morning of Day 8. Upon satisfactory safety review and completion of study-related procedures, subjects will be discharged from the study center on the morning of Day 8.
Part 2 will be a 2-period crossover study; in Period 1, subjects (n = 12) will be randomized to receive an oral 20 mg dose of CC-223 (Treatment B) under fed (n = 6) or fasted (n = 6) conditions. In Period 2, subjects will receive Treatment B under converse conditions based on treatment assignment in Period 1 (Cohort 2 or 3). Fed subjects will be served a standard high fat meal (breakfast), or its equivalent, and must be consumed within 30 minutes of serving. Dosing must occur 30 minutes (±5 minutes) after serving a subject breakfast. All subjects will remain fasted until 4 hours post dose. Subjects will be domiciled at the study center from Day -1 until the morning of Day 5 of each period. Subjects will be discharged from the study center on the morning of Day 5 upon satisfactory safety review and completion of study-related procedures. Periods 1 and 2 will be separated by a washout period of at least 7 days (no more than 10 days) from prior dose to the next dose. In certain instances, a longer washout may be acceptable if previously agreed to by the principal investigator (PI) and Celgene.
All subjects will return to the clinic within 7 to 10 days after the day of discharge in Part 1 or Period 2 of Part 2 for follow-up safety assessments.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53704
- Covance Research Unit, Inc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must understand and voluntarily sign a written informed consent document (ICD) prior to any study-related procedures being performed and be able to adhere to restrictions and examination schedules.
- Must be able to communicate with the investigator and clinical staff and to understand and comply with the requirements of the study.
- Must be a male 18 to 55 years of age (inclusive) at the time of signing the ICD, with a body mass index (BMI) (weight [kg]/(height [m2]) between 18 and 33 kg/m2 (inclusive) and weight between 60 and 100 kg (132 to 220 lbs; inclusive)
Must be healthy (at Screening and Day -1) as determined by the investigator on the basis of medical history, physical examination, clinical laboratory safety test results, vital signs, and 12 lead electrocardiograms (ECGs).
- Vital signs (systolic and diastolic blood pressure, pulse rate, and oral body temperature) will be assessed in the supine position after the subject has rested for at least 5 minutes.
- Subject must be afebrile (febrile is defined as ≥ 38.5ºC or 101.3 Fahrenheit)
- Systolic blood pressure in the range of 90 to 140 mmHg, diastolic blood pressure in the range of 60 to 90 mmHg, and pulse rate in the range of 45 to 100 bpm
- Screening fasting plasma glucose value within the normal limits of the institution and HbA1C < 6%
- Subjects (with or without vasectomy) must agree to use barrier contraception (ie, latex condom or any non-latex condom not made out of natural [animal] membrane [eg., polyurethane]) and one other method (eg., spermicide) when engaging in sexual activity with woman of child-bearing potential during study conduct, and for 90 days after the last dose of study medication.
- Must agree to refrain from donating blood or plasma (other than for this study) while participating in this study and for at least 28 days after the last dose of study drug.
Exclusion Criteria:
- Recent history (ie, within 3 years) of any clinically significant neurological, gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, endocrine, hematological, dermatological, psychological, or other major disorders.
- Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he were to participate in the study, or confounds the ability to interpret data from the study.
- Use of any prescribed systemic or topical medication within 30 days of the first dose.
- Use of any non-prescribed systemic or topical medication (including herbal medicines) within 7 days of the first dose administration (with the exception of vitamin/mineral supplements).
- Subject used any metabolic enzyme inhibitors or inducers (ie, CYP3A inducers and inhibitors or St. John's Wort) within 30 days of the first dose administration.
- Presence of any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism, and excretion, or plans to have elective or medical procedures during the conduct of the trial.
- Exposure to an investigational drug (new chemical entity) within 90 days prior to the first dose administration.
- Donation of blood or plasma within 60 days prior to the first dose administration.
- History of multiple (ie, 2 or more) drug allergies.
- Any clinical significant allergic disease (excluding non-active hay fever), excluding non-active seasonal allergies and childhood asthma cleared for at least 3 years
- History of drug abuse within 2 years prior to first dosing, or positive urine drug screening test due to illicit drugs.
- History of alcohol abuse within 2 years prior to dosing, or positive alcohol screen.
- Smokes more than 10 cigarettes, or consumes the equivalent in tobacco, per day.
- Known to have, or tests positive for, active or chronic hepatitis B or hepatitis C, or human immunodeficiency virus (HIV) antibodies
- Received vaccination (excluding seasonal flu vaccination) within 90 days of the study drug administration.
- For Part 1 Only: Prior exposure to radioactive investigational drugs within 6 months prior to check in, and prior exposure to work-related, diagnostic or therapeutic radiation within 12 months prior to check in.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 20 mg oral CC-223 with microtracer
A single 20-mg oral dose of CC-223 capsule containing a microtracer of [14C]-CC-223 solution
|
20 mg oral CC-223 capsule containing a microtracer of [14C]-CC-223 solution
20-mg oral CC-223 tablet under fasting or fed conditions
|
Experimental: 20 mg oral CC-223 fasting
A single 20-mg oral dose of CC-223 tablet under fasting conditions
|
20 mg oral CC-223 capsule containing a microtracer of [14C]-CC-223 solution
20-mg oral CC-223 tablet under fasting or fed conditions
|
Experimental: 20 mg oral CC-223 fed
A single 20-mg oral dose of CC-223 tablet under fed conditions
|
20 mg oral CC-223 capsule containing a microtracer of [14C]-CC-223 solution
20-mg oral CC-223 tablet under fasting or fed conditions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total radioactivity
Time Frame: Up to 8 days
|
Total [14C]-radioactivity in whole blood, plasma, urine and feces
|
Up to 8 days
|
Cumulative excretion of radioactivity
Time Frame: Up to 8 days
|
Cumulative excretion of Total [14C]-radioactivity (as fraction of radioactive dose) in urine and feces
|
Up to 8 days
|
Total radioactivity ratios
Time Frame: Up to 8 days
|
Total [14C]-radioactivity whole blood-to-plasma ratios
|
Up to 8 days
|
Metabolite concentration
Time Frame: Up to 8 days
|
Concentration of CC-223 and M1 metabolite (O-desmethyl-CC-223) in plasma, urine, and feces samples collected up to 14 times from the day prior to dosing to 8 days after dosing.
|
Up to 8 days
|
Cmax
Time Frame: Up to 10 days
|
Cmax: Maximum observed concentration in plasma
|
Up to 10 days
|
Tmax
Time Frame: Up to 10 days
|
Tmax: Time to maximum concentration
|
Up to 10 days
|
AUC
Time Frame: Up to 10 days
|
AUC: Area under the plasma concentration-time curve
|
Up to 10 days
|
t1/2
Time Frame: Up to 10 days
|
t1/2: Terminal half-life
|
Up to 10 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: Up to 30 days
|
Number of participants with adverse events
|
Up to 30 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Maria Palmisano, M.D., Celgene Corporation
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- CC-223-CP-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Safety and Pharmacokinetics in Healthy Volunteer Subjects
-
AstraZenecaCompletedA Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy SubjectsHealthy Subjects | Pharmacokinetics | SafetyUnited States
-
AstraZenecaCompletedHealthy Subjects | Pharmacokinetics | Tolerability | SafetyUnited Kingdom
-
Yiling Pharmaceutical Inc.CompletedPharmacokinetics | Healthy Adult Subjects | Safety and TolerabilityUnited States
-
Baystate Medical CenterCompleted
-
Astellas Pharma Europe B.V.CompletedHealthy Subjects | Pharmacokinetics | Pharmacodynamics | SafetyNetherlands
-
AstraZenecaWithdrawnHealthy Male Subjects | Pharmacokinetics | Safety | Food EffectUnited Kingdom
-
Bioniz TherapeuticsCelerionCompletedSafety and Tolerability in Healthy SubjectsUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Safety and Tolerability in ElderlyUnited States
-
XenoPort, Inc.CompletedPharmacokinetics | Healthy VolunteerUnited States
-
Endo PharmaceuticalsCompletedHealthy Volunteer Safety StudyUnited States
Clinical Trials on CC-223
-
CelgeneCompletedDiffuse Large B-Cell Lymphoma | Multiple Myeloma | Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Glioblastoma Multiforme | Neuroendocrine Tumors of Non-Pancreatic Origin | Hormone Receptor-Positive Breast CancerUnited States, Spain, United Kingdom, France
-
CelgeneCompletedCarcinoma, Non-Small-Cell Lung | Non-Small Cell Lung CancerUnited States, Spain
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, PulmonaryUnited States
-
CelgeneTerminatedLymphoma, Large B-Cell, DiffuseUnited States, France, Canada, Italy
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, PulmonaryUnited States
-
M.D. Anderson Cancer CenterBayer; Prostate Cancer FoundationCompleted
-
AmgenCompletedEnd Stage Renal Disease | Chronic Kidney Disease | Kidney Disease | Hyperphosphatemic
-
University of Southern CaliforniaNational Cancer Institute (NCI)Active, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer | Prostate Carcinoma Metastatic in the BoneUnited States
-
Sir Mortimer B. Davis - Jewish General HospitalCompleted
-
University of WashingtonBayerRecruitingCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8United States